Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: A randomized open-label controlled trial

Critical Care

Volumn 16, Issue 3, 2012, Pages

  Chytra, Ivan ^a   Stepan, Martin ^a   Benes, Jan ^a   Pelnar, Petr ^a   Zidkova, Alexandra ^a   Bergerova, Tamara ^a   Pradl, Richard ^a   Kasal, Eduard ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPICILLIN; CIPROFLOXACIN; FLUCONAZOLE; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; VORICONAZOLE; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG SAFETY; HOSPITALIZATION; HUMAN; INFECTION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MYCOSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ADULT; BACTERIAL COUNT; COMPARATIVE STUDY; CRITICAL ILLNESS; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME; TRENDS;

ADULT; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THIENAMYCINS; TREATMENT OUTCOME;

EID: 84862776118     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11405     Document Type: Article

References (49)

1. Devasahayam G, Scheld W, Hoffman P. Newer antibacterial drugs for a new century. Expert Opin Investig Drugs 2010, 19:215-234. 10.1517/13543780903505092, 2831224, 20053150.
2. Livermore D. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 2011, 66:1941-1944. 10.1093/jac/dkr262, 21700626.
3. Roberts J, Lipman J, Blot S, Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. Curr Opin Crit Care 2008, 14:390-396. 10.1097/MCC.0b013e3283021b3a, 18614901.
4. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003, 17:479-501. 10.1016/S0891-5520(03)00065-5, 14711073.
5. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003, 36:S42-S50. 10.1086/344653, 12516029.
6. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004, 2:289-300. 10.1038/nrmicro862, 15031728.
7. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998, 27:10-22. 10.1086/514622, 9675443.
8. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351. 10.1016/j.ijantimicag.2007.12.009, 18313273.
9. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45:755-773. 10.2165/00003088-200645080-00001, 16884316.
10. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007, 51:1725-1730. 10.1128/AAC.00294-06, 1855547, 17307978.
11. Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002, 19:105-110. 10.1016/S0924-8579(01)00474-5, 11850162.
12. Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005, 44:539-549. 10.2165/00003088-200544050-00007, 15871639.
13. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005, 49:1337-1339. 10.1128/AAC.49.4.1337-1339.2005, 1068632, 15793108.
14. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006, 46:1171-1178. 10.1177/0091270006291035, 16988206.
15. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005, 49:461-463. 10.1128/AAC.49.1.461-463.2005, 538854, 15616337.
16. Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010, 32:766-779. 10.1016/j.clinthera.2010.04.003, 20435246.
17. Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006, 40:219-223. 10.1345/aph.1G467, 16449546.
18. Roberts JA, Ulldemolins M, Lipman J. Meropenem: focus on its use in serious bacterial infections. Clin Med Rev Ther 2010, 2:1-14.
19. Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care 2011, 15:R206. 10.1186/cc10441, 3334750, 21914174.
20. Jeurissen A, Rutsaert R. β-lactam antibiotics in continuous infusion in critically ill patients. Crit Care 2010, 14:446. 10.1186/cc9288, 3219286, 21062510.
21. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009, 37:2071-2078. 10.1097/CCM.0b013e3181a0054d, 19384201.
22. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007, 30:11-18. 10.1016/j.ijantimicag.2007.02.002, 17442541.
23. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, . SCCM/ESICM/ACCP/ATS/SIS 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256. 10.1097/01.CCM.0000050454.01978.3B, 12682500, SCCM/ESICM/ACCP/ATS/SIS.
24. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988, 16:128-140. 10.1016/0196-6553(88)90053-3, 2841893.
25. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G, . National Kidney Foundation National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137-147. National Kidney Foundation.
26. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008, 47:S32-S40. 10.1086/590064, 18713048.
27. O'Grady NP, Barie PS, Bartlett J. Practice parameters for evaluating new fever in critically ill adult patients. Task Force of the American College of Critical Care Medicine of the Society of Critical Care Medicine in collaboration with the Infectious Disease Society of America. Crit Care Med 1998, 26:392-408. 10.1097/00003246-199802000-00046, 9468180.
28. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125:1791-1799. 10.1378/chest.125.5.1791, 15136392.
29. Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008, 68:803-838. 10.2165/00003495-200868060-00006, 18416587.
30. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 2004, 26:493-501. 10.1016/S0149-2918(04)90051-3, 15189746.
31. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002, 22:471-483. 10.1592/phco.22.7.471.33665, 11939682.
32. Lorente L, Jiménez A, Palmero S, Jiménez JJ, Iribarren JL, Santana M, Martín MM, Mora ML. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007, 29:2433-2439. 10.1016/j.clinthera.2007.11.003, 18158083.
33. Kojika M, Sato N, Hakozaki M, Suzuki Y, Takahasi G, Endo S, Suzuki K, Wakabayasi G. A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time. Jpn J Antibiot 2005, 58:452-457. 10.1038/ja.2005.59, 16379157.
34. Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010, 25:69-77. 10.1016/j.jcrc.2009.02.014, 19427167.
35. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003, 43:1116-1123. 10.1177/0091270003257225, 14517194.
36. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005, 49:4920-4927. 10.1128/AAC.49.12.4920-4927.2005, 1315965, 16304153.
37. Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Int J Antimicrob Agents 2006, 28:433-438. 10.1016/j.ijantimicag.2006.07.014, 17046212.
38. Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, Nicolau DP. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. Int J Antimicrob Agents 2007, 30:452-457. 10.1016/j.ijantimicag.2007.06.005, 17646088.
39. Jaruratanasirikul S, Limapichat T, Jullangkoon M, Aeinlang N, Ingviya N, Wongpoowarak W. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. Int J Antimicrob Agents 2011, 38:231-236. 10.1016/j.ijantimicag.2011.04.019, 21726984.
40. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363. 10.1086/510590, 17205441.
41. Merchant S, Gast C, Nathwani D, Lee M, Quintana A, Ketter N, Friedland I, Ingham M. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008, 30:717-733. 10.1016/j.clinthera.2008.04.001, 18498921.
42. Yost R, Cappelletty D. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) Study: a multicenter study. Pharmacotherapy 2011, 31:767-775. 10.1592/phco.31.8.767, 21923603.
43. Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-150. 10.1093/jac/dkp139, 19398460.
44. Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM, Richards B, Lipman J. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007, 59:285-291.
45. Lubasch A, Lück S, Lode H, Mauch H, Lorenz J, Bölcskei P, Welte T, . COPD Study Group Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. J Antimicrob Chemother 2003, 51:659-664. 10.1093/jac/dkg111, 12615868, COPD Study Group.
46. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001, 17:497-504. 10.1016/S0924-8579(01)00329-6, 11397621.
47. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, Dana A. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006, 50:3556-3561. 10.1128/AAC.00329-06, 1635208, 16940077.
48. Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007, 30:657-668. 10.2165/00002018-200730080-00002, 17696578.
49. Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 1999, 31:3-10. 10.1080/00365549950161808, 10381210.